Controlled Substances

PA-3's controlled substances architecture is the SD where federal architecture is qualitatively different from SD1-SD5: a substantive federal architecture expansion rather than withdrawal. DEA Marijuana Schedule III Final Order effective April 28, 2026 (FR Doc. 2026-08176; Vol. 91 No. 81; per MC-01), pursuant to Trump EO 14370 signed December 18, 2025 ("Increasing Medical Marijuana and Cannabidiol Research"). DOJ Final Order issued April 23, 2026 (Acting Attorney General; Order No. 6753-2026). DEA Medical Marijuana Dispensary Registration Portal opens April 29, 2026 at 9:00 AM EST with $794 annual application fee (initially payable via PayPal only); 60-day priority window through ~June 27, 2026. Adult-use cannabis remains Schedule I; only FDA-approved products + state-licensed medical cannabis rescheduled. Synthetically derived THC (delta-10) excluded; remains Schedule I. Section 280E deduction disallowance lifted effective immediately for state-licensed medical cannabis (Treasury/IRS guidance forthcoming on transitional rules); DOJ Final Order encouraged Treasury to consider "retrospective relief" from 280E for prior tax years. Prior NPRM (89 FR 70148) and hearing withdrawn April 22, 2026 (FR Doc. 2026-08178). New DEA hearing on broader rescheduling: June 29 - July 15, 2026 (recess July 3, reconvene July 6). The structural context at SD6 is the Both/And framing — overdose mortality decline ~24% from 2022 peak + Mayor Parker $100M+ wellness ecosystem expansion + structurally entrenched compound factors at Kensington (medetomidine 83% supply by March 2025; BTMPS 25%; xylazine continued co-occurrence) all operate simultaneously. Prevention Point demographics (62% white / 26% Black / 83% unhoused) document parallel-infrastructure engagement at the Kensington compound-incidence locus — distinct from the broader Black PA-3 OUD population engagement pattern ([G1-SD6-02](https://github.com/square-party/square-party-site/blob/main/reference-info/verified-pa3-domain-content/D4-food-drug/D4_foodMed_verified_2026-04-29.md#g1-sd6-02) careful framing preserved; gap-finding without pathologizing).

Legal framework

Federal statutory layer

Commerce Clause grounds federal regulation of controlled substances. Spending Clause grounds federal addiction treatment funding (SAMHSA / HRSA). Controlled Substances Act 1970, 21 U.S.C. § 801 et seq. — Schedule I-V framework; DEA registration; quotas; suspicious-order monitoring (statutory stability HIGH; foundational). Mainstreaming Addiction Treatment (MAT) Act of 2022 eliminated DATA 2000 X-waiver requirement for buprenorphine prescribing (HIGH; cross-ref SD3). Ryan Haight Online Pharmacy Consumer Protection Act 2008 — in-person evaluation requirement for controlled substance telemedicine prescribing; DEA telemedicine flexibility through December 2026.

Federal agency layer

DEA — Diversion Control Division — Philadelphia Field Division (Mid-Atlantic region; primary PA-3-relevant federal-direct controlled substance enforcement). DEA Marijuana Schedule III Final Order effective April 28, 2026 (FR Doc. 2026-08176; per MC-01); 60-day priority window through ~June 27, 2026; DEA Medical Marijuana Dispensary Registration Portal opens April 29, 2026 at 9:00 AM EST with $794 annual application fee. Administrative vulnerability MODERATE — DEA workforce stable relative to FDA; Schedule III implementation operative; new DEA hearing on broader rescheduling June 29 - July 15, 2026. SAMHSA — addiction treatment funding architecture; Region III Philadelphia; administrative vulnerability MODERATE-HIGH — federal funding pressure operative. HRSA — community health center funding cross-ref D5.

State statutory and agency layer

PA Drug Act at 35 P.S. § 780-101 et seq. — state-level controlled substance schedules; coordination with CSA. PA Medical Marijuana Act 2016 (Act 16) at 35 P.S. § 10231.101 et seq. — PA medical marijuana program; certifying-physician + patient certification + dispensary architecture; PA grower-processor + dispensary licensing. ABC-MAP (Act 191 of 2014) — PA Prescription Drug Monitoring Program. PA Department of Health — Office of Medical Marijuana — patient certification; dispensary regulation; grower-processor regulation; administrative vulnerability MODERATE. PA Office of Attorney General — narcotic enforcement.

Local statutory and agency layer

Philadelphia Code at controlled-substance + addiction-treatment interface — coordination with state and federal architectures. Philadelphia Department of Behavioral Health and Intellectual disAbility Services (DBHIDS) — primary local addiction-treatment + harm-reduction architecture anchor; Mayor Parker $100M+ wellness ecosystem expanded harm-reduction architecture; administrative vulnerability MODERATE — local capacity expanded through Mayor Parker ecosystem; federal funding pressure on Prevention Point + mobile fentanyl treatment units. PDPH coordination at addiction-treatment interface. Prevention Point as harm-reduction anchor (demographics 62% white / 26% Black / 83% unhoused at Kensington compound-incidence locus). The independent / small organization layer (XC-11) at SD6: smaller harm reduction organizations / smaller treatment programs / smaller mutual-aid programs vs. DBHIDS + Prevention Point + Mayor Parker ecosystem.

Cross-cutting structural features

The architectural pattern at SD6 is the only D4 sub-domain where federal architecture expansion (today-effective Schedule III) rather than withdrawal operates as the central material change. The MAHA-era three-pattern co-occurrence at SD6 operates differently than SD1-SD5: (a) federal architecture expansion at substance-rescheduling layer (DEA Schedule III Final Order effective April 28, 2026 per MC-01); (b) federal funding pressure at SAMHSA layer affecting Prevention Point + mobile fentanyl treatment units (XC-11 differential); (c) structurally entrenched compound factors at Kensington locus level intersecting pharmacy desert + cessation pathway reduction (cross-cut SD3 + SD5). Both-true framing critical — overdose mortality decline ~24% from 2022 peak + Mayor Parker ecosystem expansion + structurally entrenched compound factors all operate simultaneously; the decline is real and the entrenchment is real. Careful G1-SD6-02 framing preserved — gap-finding at architecture level without individual-engagement-pattern pathologizing.

Geography & representation

Data provenance. CSA statutory framework directly documented. DEA Marijuana Schedule III Final Order (FR Doc. 2026-08176; effective April 28, 2026; per MC-01) directly documented. Trump EO 14370 (December 18, 2025) directly documented. PA Medical Marijuana Act 2016 directly documented. ABC-MAP architecture directly documented. Prevention Point demographics 62% white / 26% Black / 83% unhoused directly documented. Medetomidine 83% Philadelphia drug supply by March 2025; BTMPS 25%; xylazine continued co-occurrence directly documented. Kensington compound-incidence concentration directly documented. Documented overdose mortality decline ~24% from 2022 peak directly documented. PA-3 buprenorphine prescriber density by sub-area pending (cross-ref SD3); Black PA-3 OUD-population engagement-pattern peer-reviewed literature pending F4-T2P2-SD6-1; DEA registration uptake first 60-day window through ~June 27, 2026 newly retrievable F4-T2P2-SD6-2.

PA-3 statistical profile. National OUD baseline ~7-8% U.S. population with substance use disorder; ~2.5M with OUD specifically; methadone-vs-buprenorphine racial-pattern asymmetry documented. Philadelphia OUD: Kensington compound-incidence locus with multi-substance concentration — medetomidine 83% of Philadelphia drug supply by March 2025; BTMPS 25%; xylazine continued co-occurrence; documented overdose mortality decline ~24% from 2022 peak. Prevention Point demographics: 62% white / 26% Black / 83% unhoused at the Kensington compound-incidence locus. PA-3 specific OUD prevalence at sub-area resolution pending F4-T2P2-SD6-3; Kensington geography intersects PA-3 boundary partially. PA medical marijuana: ~430,000 PA medical marijuana patients (PA DoH Office of Medical Marijuana baseline); ~190 PA dispensaries; PA-3 dispensary count pending. DEA Schedule III: $794 annual application fee; 60-day priority window through ~June 27, 2026; PA-3 dispensary registration uptake during window pending F4-T2P2-SD6-2. Mayor Parker ecosystem: $100M+ wellness ecosystem expansion documented; mobile fentanyl treatment unit scope; expanded harm-reduction architecture.

Geographic variation across four sub-areas. North/Northwest Philadelphia Core — Kensington-adjacent boundary intersects northern portion; documented compound-incidence locus partially within PA-3 boundary; SD1 + SD3 + SD5 + SD6 simultaneous concentration most acute at this sub-area boundary; concentrated unhoused population (cross-cut Source 35 Prevention Point 83% unhoused); harm-reduction services concentrated. West Philadelphia Core — documented OUD prevalence at Cobbs Creek + portions; pharmacy desert post-Rite-Aid affects buprenorphine pharmacy availability vector (cross-ref SD3); harm-reduction services available through DBHIDS coordination. Northwest Philadelphia (Mt. Airy) — lower documented OUD prevalence concentration; mixed-income demographic; medical marijuana patient concentration variable. South/Southwest Philadelphia — documented OUD prevalence pattern; pharmacy desert post-Rite-Aid affects buprenorphine pharmacy availability + cessation pharmacotherapy access vector (cross-ref SD3 + SD5); harm-reduction services available.

Constituent profiles

Profile 1: PA-3 OUD patient accessing buprenorphine post-X-waiver in pharmacy-desert sub-area

Constituent type: a PA-3 constituent OUD patient seeking buprenorphine treatment via post-MAT-Act prescribing eligibility expansion — residing in a documented pharmacy-desert sub-area where Rite Aid closure has reduced buprenorphine pharmacy availability.

Pathway through the institutional system. OUD diagnosis + treatment-pursuit at MAT-Act-eligible prescriber. MAT Act 2022 eliminated DATA 2000 X-waiver requirement; ~3,000-4,000 PA-3 prescriber-eligible cadre. Prescription written; pharmacy fill subject to suspicious-order monitoring constraint; methadone vs. buprenorphine racial-pattern asymmetry documented. Decision point: pharmacy desert post-Rite-Aid (cross-ref SD3) reduces buprenorphine pharmacy availability vector at sub-area level.

XC-11 application. Smaller treatment programs may have less capacity to absorb federal funding pressure than DBHIDS or larger institutional programs; smaller programs serving specific PA-3 community subsets carry differential continuation-vulnerability. SAMHSA federal funding pressure on Prevention Point + mobile fentanyl treatment units operates differently against smaller harm-reduction organizations.

Outcome. The patient experiences the post-X-waiver federal expansion (MAT Act 2022) operative simultaneous with pharmacy desert post-Rite-Aid + suspicious-order monitoring constraint + methadone-vs-buprenorphine racial-pattern asymmetry. Cross-cut SD3 G1-SD3-06 and SD6 G1-SD6-01: the buprenorphine pharmacy availability gap operates at the federal-state-local intersection where the MAT Act expanded prescribing capacity at the same moment PA pharmacy infrastructure attrition narrowed the fill pathway (G1-SD6-01 + G1-SD6-04; cross-ref SD3).

Profile 2: PA-3 resident at the Kensington compound-incidence locus boundary

Constituent type: a PA-3 constituent residing in the northern boundary portion of North/Northwest Philadelphia Core where the Kensington compound-incidence locus partially intersects PA-3 — within the geography of documented structurally entrenched compound factors.

Pathway through the institutional system. Presence at Kensington compound-incidence locus geography (boundary partially intersects N./Northwest Phila Core). Parallel-infrastructure (harm-reduction + emergency response + outreach) engagement at locus; Prevention Point demographics 62% white / 26% Black / 83% unhoused document the locus engagement pattern at the organizational level.

Critical framing per G1-SD6-02 — gap-finding without pathologizing. Prevention Point demographics represent the parallel-infrastructure engagement pattern at the locus itself, not the broader Black PA-3 OUD population engagement pattern. Black PA-3 OUD patients in PA-3 sub-areas with documented OUD prevalence engage treatment pathways through varied infrastructure: traditional treatment programs, peer-support programs, faith-based programs, family / community networks, and other pathways (peer-reviewed Black PA-3 OUD-population engagement-pattern literature is the verification target — F4-T2P2-SD6-1). The gap-finding is at the architecture level (parallel-infrastructure organizational engagement at the locus + treatment-pathway diversity at broader population level + structural-pattern documentation), not at the individual-engagement-pattern pathologizing level.

Outcome. The resident experiences the compound-incidence locus geography where medetomidine 83% supply by March 2025, BTMPS 25%, and xylazine continued co-occurrence produce a compound chronic-illness profile. Both-true framing critical: overdose mortality decline ~24% from 2022 peak + Mayor Parker $100M+ wellness ecosystem expansion + structurally entrenched compound factors all operate simultaneously; the decline is real and the entrenchment is real (G1-SD6-05; G1-SD6-02).

Profile 3: PA-3 medical marijuana patient under the today-effective Schedule III architecture

Constituent type: a PA-3 constituent medical marijuana patient with qualifying-condition certification under PA Act 16 of 2016 — seeking dispensary access under the today-effective DEA Schedule III Final Order architecture.

Pathway through the institutional system. Certifying physician registration + patient certification under PA Act 16 of 2016; dispensary access at PA-3-located dispensary. DEA Marijuana Schedule III Final Order effective April 28, 2026 (FR Doc. 2026-08176; per MC-01) creates new federal-state coordination pathway requirement. 60-day priority window through ~June 27, 2026 for medical marijuana licensee DEA registration; $794 annual application fee (initially payable via PayPal only). Section 280E deduction disallowance lifted effective immediately for state-licensed medical cannabis; Treasury/IRS guidance forthcoming on transitional rules; DOJ Final Order encouraged Treasury to consider "retrospective relief" from 280E for prior tax years.

Implementation-time-delay note. Schedule III legal-layer effective April 28, 2026; felt-reality reach to PA-3 medical marijuana patient at dispensary access layer pending dispensary registration completion + insurance / Medicare-Medicaid coverage adaptation pathway operationalization. The new DEA hearing on broader rescheduling June 29 - July 15, 2026 is the next inflection point.

XC-11 application. Smaller dispensary operators (independent vs. multi-state operators) under PA Act 16 architecture carry differential capacity to navigate the dual federal-state regulatory pathway during the 60-day priority window. The $794 annual application fee + the dispensary registration administrative burden + the Section 280E transitional-rule navigation operate differentially on smaller operators.

Outcome. The medical marijuana patient experiences the federal architecture expansion (today-effective Schedule III) as a federal-state coordination pathway requirement with implementation-time-delay between legal-layer effective date and operational reach. Adult-use cannabis remains Schedule I; synthetically derived THC (delta-10) excluded; only FDA-approved products + state-licensed medical cannabis rescheduled (G1-SD6-06; MC-01).

Conversational note

The most consequential thing to understand about D4 SD6 from a PA-3 representation perspective is that SD6 is the only D4 sub-domain where federal architecture is qualitatively different from SD1-SD5 — a substantive federal architecture expansion through the DEA Marijuana Schedule III Final Order effective April 28, 2026 (FR Doc. 2026-08176; per MC-01) rather than withdrawal. The 60-day priority window for medical marijuana licensee DEA registration operates through ~June 27, 2026; the DEA Medical Marijuana Dispensary Registration Portal opens April 29, 2026 at 9:00 AM EST with a $794 annual application fee. Section 280E deduction disallowance is lifted effective immediately for state-licensed medical cannabis (with Treasury/IRS guidance forthcoming on transitional rules; DOJ Final Order encouraged Treasury to consider retrospective relief for prior tax years). Adult-use cannabis remains Schedule I; synthetically derived THC (delta-10) is excluded; only FDA-approved products and state-licensed medical cannabis are rescheduled. The new DEA hearing on broader rescheduling is scheduled for June 29 - July 15, 2026 (recess July 3, reconvene July 6). The architecture is implementing an expansion at the substance-rescheduling layer — qualitatively different from the SD1-SD5 withdrawal pattern.

At the same moment, the structurally entrenched compound-incidence factors at Kensington persist: medetomidine 83% of Philadelphia drug supply by March 2025; BTMPS 25%; xylazine continued co-occurrence. Mayor Parker $100M+ wellness ecosystem expansion is operative; documented overdose mortality decline ~24% from 2022 peak coexists with the entrenchment. Both-true framing critical: the decline is real and the entrenchment is real; we preserve both as simultaneous documented patterns rather than collapsing one into the other. The federal funding pressure at SAMHSA layer affecting Prevention Point + mobile fentanyl treatment units operates within the Mayor Parker ecosystem expansion. SD6 is the only D4 sub-domain where federal agency layer (DEA) carries MODERATE rather than HIGH or EXTREME administrative vulnerability — DEA workforce is stable relative to FDA. The MAHA-era three-pattern co-occurrence at SD6 operates at SAMHSA federal funding pressure + state-architecture stability (PA Act 16 + ABC-MAP HIGH stability) + the today-effective Schedule III as a substantive federal architecture expansion rather than withdrawal.

The XC-11 differential at SD6 lands on smaller harm-reduction / treatment / mutual-aid organizations. DBHIDS + Prevention Point + Mayor Parker $100M+ wellness ecosystem operate as the primary local-layer architecture; smaller harm-reduction organizations + smaller treatment programs + smaller mutual-aid programs operate alongside this primary architecture with less capacity to absorb federal funding pressure. Whether the Mayor Parker ecosystem's expansion reaches or bypasses smaller harm-reduction organizations is a structural question — expansion of large-anchor capacity is not equivalent to expansion of smaller-organization capacity. The federal funding pressure on Prevention Point + mobile fentanyl treatment units may concentrate effects on smaller organizations differentially.

The careful G1-SD6-02 framing — gap-finding without pathologizing — is methodologically critical and is preserved. Prevention Point demographics 62% white / 26% Black / 83% unhoused document parallel-infrastructure organizational engagement at the Kensington compound-incidence locus, not the broader Black PA-3 OUD population engagement pattern. Black PA-3 OUD patients in PA-3 sub-areas with documented OUD prevalence engage treatment pathways through varied infrastructure: traditional treatment programs, peer-support programs, faith-based programs, family / community networks, and other pathways. Peer-reviewed literature on Black PA-3 OUD-population engagement-pattern is the verification target (F4-T2P2-SD6-1). The gap-finding operates at the architecture level — parallel-infrastructure organizational engagement at the locus + treatment-pathway diversity at broader population level + structural-pattern documentation. The gap-finding does not operate at the individual-engagement-pattern pathologizing level — it preserves the structural-architecture analytical posture without inferring individual-engagement-pattern pathology.

For the PA-3 OUD patient accessing buprenorphine post-X-waiver in a pharmacy-desert sub-area, the PA-3 resident at the Kensington compound-incidence locus boundary, and the PA-3 medical marijuana patient under the today-effective Schedule III architecture, the experience of the federal-state-local controlled substances architecture is the doubly-narrowed access pathway, the parallel-infrastructure engagement geography, and the federal-state coordination pathway requirement they encounter. The structural representation question for SD6 is whether federal House representation engages DEA Schedule III implementation oversight + the broader-rescheduling hearing June 29 - July 15, 2026, SAMHSA federal funding pressure on Prevention Point + mobile fentanyl treatment units, the post-pharmacy-desert buprenorphine pharmacy availability gap (cross-cut SD3 + SD5), and the smaller harm-reduction / treatment / mutual-aid organization differential (XC-11).

Where this leads

Federal House representation has direct levers on DEA Schedule III implementation oversight including the 60-day priority window through ~June 27, 2026 and the broader-rescheduling hearing June 29 - July 15, 2026 (G1-SD6-06; MC-01); SAMHSA federal funding pressure on Prevention Point + mobile fentanyl treatment units (G1-SD6-03); post-pharmacy-desert buprenorphine pharmacy availability gap (G1-SD6-01 + G1-SD6-04; cross-ref SD3); DEA telemedicine flexibility extension beyond December 2026 expiration including Ryan Haight in-person evaluation requirement reactivation (G1-SD6-07); Section 280E transitional-rule oversight + retrospective relief consideration for state-licensed medical cannabis (cross-cutting MC-01); structurally entrenched compound-incidence factors at Kensington locus chronic-illness peer-reviewed literature retrieval (G1-SD6-05; F4-T2P2-SD6-4); and smaller harm-reduction / treatment / mutual-aid organization differential (G1-SD6-08; XC-11 application). Indirect levers operate through congressional delegation coordination on Mayor Parker $100M+ wellness ecosystem expansion at federal-state-local interface, on PA Medical Marijuana Act 2016 dispensary registration uptake during the 60-day priority window, and on the broader-rescheduling hearing outcome at the adult-use cannabis Schedule I status question.

The next sub-domain — Federal Regulatory Architecture (synthesis) — synthesizes federal-cluster simultaneity (5 of 6 D4 sub-domains at HIGH or EXTREME federal-agency administrative vulnerability composite as of execution), the MAHA-era three-pattern co-occurrence framing (rule withdrawal + capacity erosion + data-infrastructure rollback per MC-07 + MC-08), XC-11 independent / small organization cross-cutting pattern, and the Compound Disadvantage Geography Matrix as central D4 finding-presentation infrastructure.